A dose-escalation regimen of trimethoprim–sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases

REFERENCES

• Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246–51.
   PubMed Web of Science ®Google Scholar
• Li J, Huang XM, Fang WG, Zeng XT. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006;12:114–7.
   PubMed Web of Science ®Google Scholar
• Hugle B, Solomon M, Harvey E, James A, Wadhwa A, Amin R, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken). 2010;62:1661–4.
   PubMed Web of Science ®Google Scholar
• Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161–5.
   PubMed Web of Science ®Google Scholar
• Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associ-ated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis. 1997;25:215–8.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36:2004–9.
   PubMed Web of Science ®Google Scholar
• Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, et al. Pneumocystis carinii pneumonia: a major com-plication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med. 1995;151:795–9.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiro-veci pneumonia in giant cell arteritis: a case series. Arthritis Care Res (Hoboken). 2011;63:761–5.
   PubMed Web of Science ®Google Scholar
• Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42:780–9.
   PubMed Web of Science ®Google Scholar
• Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, et al. Clinical and radiological features of Pneumocystis pneu-monia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med. 2008;47:915–23.
   PubMed Web of Science ®Google Scholar
• Monnet X, Vidal-Petiot E, Osman D, Hamzaoui 0, Durrbach A, Goujard C, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care. 2008;12:R28.
   Google Scholar
• Enomoto T, Azuma A, Kohno A, Kaneko K, Saito H, Kametaka M, et al. Differences in the clinical characteristics of Pneumo-cystis jiroveci pneumonia in immunocompromised patients with and without HIV infection. Respirology. 2010;15:126–31.
   PubMed Web of Science ®Google Scholar
• Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneu-mocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:1052–9.
   PubMed Web of Science ®Google Scholar
• Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium-or high-dose corticosteroid therapy. Mod Rheumatol. 2005; 15:91–6.
   Google Scholar
• Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effec-tiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immuno-suppressive therapy. Arthritis Rheum. 2000;43:1841–8.
   Google Scholar
• Yamazaki H, Nanki T, Miyasaka N, Harigai M. Methotrexate and trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis. J Rheumatol 2011;38:777; author reply 778.
   Google Scholar
• Milstone AM, Balakrishnan SL, Foster CB, Chen A. Failure of intravenous pentamidine prophylaxis to prevent pneumocystis pneumonia in a pediatric hematopoietic stem cell transplant (HSCT) patient. Pediatr Blood Cancer. 2006;47:859–60.
   PubMed Web of Science ®Google Scholar
• Para MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black JR. Reduced toxicity with gradual initiation of trimetho-prim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr. 2000;24:337–43.
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332:693–9.
   PubMed Web of Science ®Google Scholar
• Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients with rheu-matoid arthritis treated with infiiximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61:305–12.
   PubMed Web of Science ®Google Scholar
• Leoung GS, Stanford JF, Giordano MF, Stein A, Tones RA, Giffen CA, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184:992–7.
   PubMed Web of Science ®Google Scholar
• Soffritti S, Ricci G, Prete A, Rondelli R, Menna G, Pession A. Successful desensitization to trimethoprim--sulfamethoxazole after allogeneic haematopoietic stem cell transplantation: pre-liminary observations. Med Pediatr Oncol. 2003;40:271–2.
   PubMedGoogle Scholar
• Koopmans PP, Burger DM. Managing drug reactions to sulfon-amides and other drugs in HIV infection: desensitization rather than rechallenge? Pharm World Sci. 1998;20:253–7.
   Google Scholar
• Caumes E, Guermonprez G, Winter C, Katlama C, Bricaire F. A life-threatening adverse reaction during trimethoprim-sulfa-methoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:1313–4.
   Google Scholar
• Smith CL, Brown I, Torraca BM. Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;25:1477–8.
   Google Scholar
• Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythe-matosus. J Rheumatol. 2003;30:480–4.
   Google Scholar
• Jeffries M, Bruner G, Glenn S, Sadanandan P, Carson CW, Harley JB, et al. Sulpha allergy in lupus patients: a clinical per-spective. Lupus. 2008;17:202–5.
   PubMed Web of Science ®Google Scholar
• Fisher RG, Nageswaran S, Valentine ME, McKinney RE Jr. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dos-ages of trimethoprim-sulfamethoxazole. AIDS Patient Care STDS. 2001;15:263–9.
   Google Scholar